Agomab Therapeutics NV Adrs (AGMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | |
| Cash Flows From Operating Activities | |
| Net Income | -52,771 |
| Depreciation Amortization | 353 |
| Accounts payable and accrued liabilities | -551 |
| Other Working Capital | -1,127 |
| Other Operating Activity | 9,011 |
| Operating Cash Flow | $-45,085 |
| Cash Flows From Investing Activities | |
| Other Investing Activity | -3,507 |
| Investing Cash Flow | $-3,507 |
| Cash Flows From Financing Activities | |
| Other Financing Activity | -355 |
| Financing Cash Flow | $-355 |
| Beginning Cash Position | 200,418 |
| End Cash Position | 151,472 |
| Net Cash Flow | $-48,947 |
| Free Cash Flow | |
| Operating Cash Flow | -45,085 |
| Free Cash Flow | -45,085 |